Salmeterol/Fluticasonpropionaat 25 microgram/125 microgram/dosis Vincion, aërosol, suspensie Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

salmeterol/fluticasonpropionaat 25 microgram/125 microgram/dosis vincion, aërosol, suspensie

vincion bv westzijde 416 1506 gm zaandam - fluticasonpropionaat 125 µg/dosis ; salmeterolxinafoaat 36,3 µg/dosis samenstelling overeenkomend met ; salmeterol 25 µg/dosis - aërosol, suspensie - norfluraan, - salmeterol and fluticasone

Salmeterol/Fluticasonpropionaat 25 microgram/250 microgram/dosis Vincion, aërosol, suspensie Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

salmeterol/fluticasonpropionaat 25 microgram/250 microgram/dosis vincion, aërosol, suspensie

vincion bv westzijde 416 1506 gm zaandam - fluticasonpropionaat 250 µg/dosis ; salmeterolxinafoaat 36,3 µg/dosis samenstelling overeenkomend met ; salmeterol 25 µg/dosis - aërosol, suspensie - norfluraan, - salmeterol and fluticasone

Purevax RCPCh Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Estradiol Valeraat 1 mg / Dienogest 2 mg Laboratorios León Farma, filmomhulde tabletten Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

estradiol valeraat 1 mg / dienogest 2 mg laboratorios león farma, filmomhulde tabletten

laboratorios leon farma, s.a. c/la vallina s/n, pol. ind. 24008 navatejera (spanje) - dienogest 2 mg/stuk ; estradiolvaleraat 1 mg/stuk samenstelling overeenkomend met ; estradiol 0,76 mg/stuk - filmomhulde tablet - ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; maÏszetmeel ; maÏszetmeel, gepregelatineerd ; polyvinylalcohol (e 1203) ; povidon k 30 (e 1201) ; talk (e 553 b) ; titaandioxide (e 171), ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; maÏszetmeel ; maÏszetmeel, gepregelatineerd ; polyvinylalcohol (e1203) ; povidon k 30 (e 1201) ; talk (e 553 b) ; titaandioxide (e 171), - dienogest and estrogen

Etonogestrel/Ethinylestradiol Leon Farma 0,120 mg/0,015 mg per 24 uur, hulpmiddel voor vaginaal gebruik Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

etonogestrel/ethinylestradiol leon farma 0,120 mg/0,015 mg per 24 uur, hulpmiddel voor vaginaal gebruik

laboratorios leon farma, s.a. c/la vallina s/n, pol. ind. 24008 navatejera (spanje) - ethinylestradiol 3,5 mg/stuk ; etonogestrel 11 mg/stuk - hulpmiddel voor vaginaal gebruik - copolymeer van ethyleen-vinylacetaat (28 pct. vinylacetaat) ; polyuretaan, - vaginal ring with progestogen and estrogen

Vantavo (previously Alendronate sodium and colecalciferol, MSD) Europese Unie - Nederlands - EMA (European Medicines Agency)

vantavo (previously alendronate sodium and colecalciferol, msd)

n.v. organon - alendronic acid, colecalciferol - osteoporose, postmenopauze - geneesmiddelen voor de behandeling van botziekten - behandeling van postmenopauzale osteoporose bij patiënten met een risico op vitamine-d-insufficiëntie. vantavo vermindert het risico van wervel-en heupfracturen. behandeling van postmenopauzale osteoporose bij patiënten die niet ontvangen van vitamine-d-suppletie en risico van de vitamine-d-insufficiëntie. vantavo vermindert het risico van wervel-en heupfracturen.

Purevax RC Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rc

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Purevax RCCh Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rcch

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. onsets van immuniteit zijn aangetoond 1 week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus en chlamydophila felis componenten. de duur van de immuniteit is 1 jaar na de laatste (her) vaccinatie.

Purevax RCP FeLV Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh FeLV Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rcpch felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.